Casey Eye Institute, Oregon Health and Science University.
Department of Ophthalmology - Casey Eye Institute, Oregon Health and Science University, VA Portland Healthcare System, Portland, Oregon, USA.
Curr Opin Ophthalmol. 2021 Nov 1;32(6):574-582. doi: 10.1097/ICU.0000000000000809.
Here, we provide an overview of Vogt-Koyanagi-Harada disease (VKH), including recent updates in our understanding of disease pathophysiology, classification and therapeutics.
Advancements in bioinformatics, metabolomics and genomics investigations continue to illuminate VKH pathogenesis, and may provide insight into future therapeutic options. Multimodal imaging is indispensable in the initial evaluation of VKH, and is becoming increasingly important in understanding disease pathogenesis, as well as monitoring therapeutic response. Enhanced VKH classification criteria, released in 2021, provide standardized guidelines and terminology for clinical and research purposes.
Modern research and imaging techniques continue to improve our understanding of VKH; more work is needed to further elucidate pathogenic mechanisms and establish optimal therapeutic recommendations.
本文概述了 Vogt-小柳原田病（VKH），包括我们对疾病病理生理学、分类和治疗的最新理解。
生物信息学、代谢组学和基因组学研究的进展不断阐明 VKH 的发病机制，并可能为未来的治疗选择提供思路。多模态成像在 VKH 的初始评估中不可或缺，并且在了解疾病发病机制以及监测治疗反应方面变得越来越重要。2021 年发布的增强型 VKH 分类标准为临床和研究目的提供了标准化的指南和术语。
现代研究和成像技术不断提高我们对 VKH 的认识；需要进一步阐明发病机制并建立最佳治疗建议。
